Related Experiment Videos

Increasing Enterobacter bacteremia in pediatric patients

J Andresen1, B I Asmar, A S Dajani

  • 1Department of Pediatrics, Wayne State University, Detroit, MI.

Insights

Enterobacter bacteremia is a common nosocomial infection, often caused by Enterobacter cloacae. Initial treatment should combine a beta-lactam with aminoglycosides or trimethoprim-sulfamethoxazole due to rising resistance.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Hospital Epidemiology

Background:

  • Enterobacter bacteremia represents a significant nosocomial infection, particularly in pediatric settings.
  • Enterobacter species, notably Enterobacter cloacae, are frequent Gram-negative pathogens in hospital-acquired bacteremia.
  • Patients often present with underlying risk factors, including central venous catheter use.

Purpose of the Study:

  • To analyze the epidemiology and antimicrobial susceptibility patterns of Enterobacter bacteremia.
  • To evaluate trends in resistance to commonly used antibiotics, including third-generation cephalosporins.
  • To provide evidence-based recommendations for initial antimicrobial therapy.

Main Methods:

  • Retrospective analysis of 32 Enterobacter bacteremia episodes in 30 patients from September 1989 to November 1992.
  • Identification and species characterization of Enterobacter isolates.
  • Antimicrobial susceptibility testing of blood isolates.

Main Results:

  • Fifty-six percent of episodes were nosocomial, with Enterobacter accounting for 14% of all Gram-negative nosocomial bacteremias.
  • High resistance rates were observed for extended-spectrum penicillins and third-generation cephalosporins.
  • Low resistance was noted for aminoglycosides and trimethoprim-sulfamethoxazole (TMP/SMX); resistance to third-generation cephalosporins increased over time.

Conclusions:

  • Enterobacter bacteremia is a prevalent nosocomial infection with increasing resistance to third-generation cephalosporins.
  • Empirical therapy should consider combination regimens, such as a beta-lactam with an aminoglycoside or TMP/SMX.
  • Close monitoring of antimicrobial resistance patterns is crucial for effective patient management.

Related Concept Videos